Our data tested the synergistic effect of the combination of rapamycin+AICAR for treatment of kidney tumorigenesis in AML human and in TSC2+/− and TSC−/− fresh tubular cells isolated from normal and tumor kidney of TSC2+/− mouse and in TSC2+/− mouse model. This evidence concerns the gene TSC1 and neoplasm.